Thromb Haemost 1984; 52(02): 160-163
DOI: 10.1055/s-0038-1661163
Original Article
Schattauer GmbH Stuttgart

Pharmacokinetics and Anticoagulant Effect of Hirudin in Man

F Markwardt
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G.D.R.
,
G Nowak
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G.D.R.
,
J Stürzebecher
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G.D.R.
,
Uta Grießbach
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G.D.R.
,
P Walsmann
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G.D.R.
,
G Vogel
*   The Department of Medicine, Division of Haemostaseology, Medical Academy Erfurt, Erfurt, G.D.R.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 29. März 1984

Accepted 05. Juli 1984

Publikationsdatum:
19. Juli 2018 (online)

Summary

The pharmacokinetics and the effects on the haemostatic system of hirudin were assessed in six healthy subjects after single intravenous or subcutaneous dose (1000 AT-U/kg). When hirudin was given intravenously first-order elimination kinetics followed the initial distribution phase. The decline in plasma hirudin concentration was most adequately expressed by a biexponential equation describing a two compartment model. A mean elimination half-life of 0.84 hr and a mean volume of distribution of 12.9 1 were calculated. After subcutaneous injection a low hirudin level (∼0.5 AT-U/ml) was maintained for a prolonged period of time.

In the 24 hour-urine up to 50 per cent of the administered amount of hirudin was excreted in active form.

Thrombin time, partial thromboplastin time and prothrombin time measured in plasma samples ex vivo were prolonged dependent on the hirudin plasma level. Platelet counts, fibrinogen level and the fibrinolytic system were unchanged. Bleeding time was prolonged twice at maximum.

Subcutaneous or intravenous administration of pure hirudin was tolerated without side-effects.

 
  • References

  • 1 Markwardt F. Hirudin as an inhibitor of thrombin. In: Methods in Enzymology Proteolytic Enzymes. Perlmann GE, Lorand L. (eds) Academic Press; New York, London: 1970. 19 924-932
  • 2 Walsmann P, Markwardt F. Biochemische und pharmakologische Aspekte des Thrombininhibitors Hirudin. Pharmazie 1981; 36: 653-659
  • 3 Markwardt F. Pharmacology of hirudin. Trends Pharmacol Sci. 1984 (in press)
  • 4 Markwardt F. On the pharmacology of hirudin. Thromb Haemostas 1981; 46: 296 (Abstr.)
  • 5 Markwardt F, Hauptmann J, Nowak G, Kleßen Ch, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemostas 1982; 47: 226-229
  • 6 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombininhibitors Hirudin. Hoppe Seylers Z Physiol Chem 1967; 348: 1381-1386
  • 7 Walsmann P. Untersuchungen zur Affinitätschromatographie von Hirudin an trägerfixiertem Thrombin. Pharmazie 1981; 36: 860-861
  • 8 Grießbach Uta, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res. 1984 (in press)
  • 9 Biggs R, MacFarlane RG. Human Blood Coagulation and Its Disorders. Blackwell Scientific Publications; Oxford: 1962
  • 10 Koller F, Ducken F. Thrombose und Embolie. Schattauer, Stuttgart; New York: 1983
  • 11 Jürgens J, Beller FK. Klinische Methoden der Blutgerinnungsanalyse. Thieme; Stuttgart: 1959
  • 12 Markwardt F. Vergleichende Untersuchungen zur antithrombotischen Wirkung von Heparin und Hirudin. In: Haemostase, Thrombophilie und Arteriosklerose. van de Loo J, Asbeck F. (eds) Schattauer, Stuttgart; New York: 1982. pp 804-807
  • 13 Markwardt F, Nowak G, Hoffmann J. Comparative studies on thrombin inhibitors in experimental microthrombosis. Thromb Haemostas 1983; 49: 235-237